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(3,584 cancers, 88,514 genital warts annually). Head and neck cancers represent the
majority of additional cancers avoided. Boys’ vaccination would allow a further
reduction in females’ cases thanks to indirect protection. CONCLUSIONS: Model
simulations were robust as they replicated US published results. This first analysis
showed that vaccinating boys in addition of girls had the potential to prevent a
significant number of additional cases. Country specific analysis will be useful to
take into account different vaccination programs in place.
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OBJECTIVES: Since the inception of economic evaluation for new drug reimburse-
ment decisions in 2007, there have been modifications on this policy. While this
reflects in itself the imperfect systematic adoption of economic evaluation from
the beginning, it has been pointed out that the current scheme relying on the proof
of cost-effectiveness value remains silent on crucial issues related to the opportu-
nity cost from a system perspective and fair access to treatment. This study was
aimed to discover how much social judgment was prudently considered in the
reimbursement decision process especially for oncology medications in Korea.
METHODS: Public review documents drawn by the Health Insurance Review and
Assessment Agency on oncology medications were collected and analyzed to ex-
amine the concrete shape of public accountability. For external comparison, cor-
responding public documents presented by the Pharmaceutical Benefits Advisory
Committee of Australia and the National Institute for Health and Clinical Excel-
lence of UK were also pulled together and analyzed. Finally, not only clinical and
economic evidence factors but also non-evidentiary factors such as equity and
historical precedent revealed through the analytical works were discussed in depth
by interviewing oncologists as representative stakeholders. RESULTS: Among 12
cancer drugs, five received positive decision from January, 2007 to June, 2009. Clin-
ical study data and price of drugs seemed the mostly considered standard for
reimbursement decision. The social judgment in this study implied the reconsid-
eration on the following issues: 1) the composition of Drug Reimbursement Evalu-
ation Committee; 2) the rationale of using cost-effectiveness data; 3) equity for rare
cancer patients; 4) words clarity in public documents; 5) transparent decision pro-
cess; and 6) budget impact results. CONCLUSIONS: Besides focusing on the im-
provement of technical evidence in HTA, a greater effort should be made for the
reasonable decision process reflecting societal desirability, public agreement and
judgments on social value.
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OBJECTIVES: Anti-cancer drug formulary has been managed by the government in
Korea and needs to be updated for better clinical outcomes. This study was to
evaluate current anti-cancer drug formulary focusing on pancreatic neuroendo-
crine tumors (PNET) and then propose the new formulary reimbursement criteria.
METHODS: The drugs on the formulary and the drugs approved for the treatment
of PNET were reviewed whether their use and reimbursement was appropriate in
the view of the evidence-based approach. The oncology textbooks and clinical
practice guidelines were reviewed also. PubMed search for the primary drug liter-
ature was performed with MeSH terms (pneuroendocrine tumors, pancreatic neo-
plasms, islet cell adenoma, islet cell carcinoma, and gastro-enteropancreatic neu-
roendocrine tumor) and the limits (clinical trial, and publication date to April 30,
2011). Published clinical research data were critically rated with the pre-deter-
mined literature evidence strength levels and the new formulary was proposed.
RESULTS:Only one anti-cancer drug (sunitinib) was approved in Korea, although it
was not proposed as a first-line in the clinical guidelines (NCCN, ESMO) and a
textbook (Abeloff’s). Although it was not on the national formulary list, a recently
published randomized controlled phase 3 trial would support its use in a certain
type of PNET as a primary chemotherapy. The already listed drugs revealed to be
evidence-supported but with relatively weak strength levels. National formulary
appeared to be reformulated with refined criteria (drug dosage and cancer types,
etc). CONCLUSIONS: Sunitinib should be listed on the national anti-cancer drug
formulary with a restricted reimbursement criteria of “treatment of unresectable
or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease
progression in adults” as described in the approved indication and pivotal clinical
research data. Next step of the research of this area would be to examine clinical
outcomes with this formulary change.
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OBJECTIVES: Cervical cancer is the third most common gynecologic cancer in the
United States. Currently there are two proven approaches to cervical cancer pre-
vention: conventional cytology screening and human papillomavirus (HPV) vacci-
nation. Prevention guidelines recommend screening every one to three years after
onset of sexual activity. In addition, many states have passed legislation to require
mandatory HPV vaccination for school children. The study aims to compare the
cost-effectiveness of HPV vaccination combined with conventional cytology
screening versus HPV vaccination alone on cervical cancer prevention in the US.
METHODS:A decision tree was used to estimate the lifetime costs (in 2004 US$) and
outcomes for U.S. women receiving HPV vaccination or mandatory HPV vaccina-
tion combined with conventional cytology screening from the societal perspective.
The costs and epidemiological data were derived from published literature and
health institution websites. Outcomes included life expectancy and quality-ad-
justed life years (QALYs) gained. RESULTS: The incremental cost-effectiveness ra-
tio (ICER) for HPV vaccination combined with the triennial screening compared to
vaccination alone was $251,965 per QALY gained. The result was most sensitive to
the total costs of conventional cytology screening. When the total costs of conven-
tional cytology screening varied from $30 to $319, the ICER increased from $98,669
to $1,006,860 per QALY gained. When increasing the frequency of screening to
biennial and annual, the ICER of HPV vaccination combined with screening com-
pared to vaccination alone changed to $335,533 and $592,991 per QALY gained
respectively. CONCLUSIONS: These results indicate that conventional cytology
screening provides little benefit beyond that provided by HPV vaccination. They
suggest that routine cytology screening should no longer be recommended for
women who have been successfully vaccinated.
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OBJECTIVES: Expensive hospital anti-cancer drugs are funded separately from the
activity-based payments. Reimbursement tariffs are set for a list of drugs including
a large proportion of anti-cancer drugs. This funding aims to ensure equity of
access to innovation throughout the French territory. Our objective was to describe
the use of the expensive anti-cancer drugs in French hospitals and to investigate
whether differences existed between the public and private sector and between
regions. METHODS: We used a sample of 448 hospitals authorized to deliver che-
motherapies. The Groupement pour l’Elaboration et la Réalisation de Statistique
provided the sales per drug and per hospital in the year 2008. Hospital character-
istics were extracted from two national surveys (Programme de Médicalisation des
Systèmes d’Information and Statistique Annuelle des Etablissements de santé). We
conducted a multilevel analysis. The dependent variable was the mean expendi-
ture per chemotherapy session and per hospital. Independent variables were hos-
pital capacity, the volume of activity, case-mix for chemotherapies and the per-
centage use of biological drugs. At the regional level, we used the mean annual
wage, inequality of wage distribution, the density of general practitioners, cancer
incidence and mortality. RESULTS: The sales of anti-cancer drugs were estimated
at 1713 million Euros. The mean expenditure per chemotherapy session was € 923
[CI: 890-954]. It was significantly higher in the private sector: €970 versus €891,
p0.02. At the hospital level, a case-mix of specialized chemotherapies for breast
cancers and the percentage use of biological drugs were associated with a higher
expenditure of anti-cancer drugs per session. There were no differences between
the mean expenditures per region. CONCLUSIONS: The absence of disparities in
the use of anti-cancer drugs between regions suggests that the reimbursement
tariffs have promoted equal access to innovative treatments throughout the terri-
tory.
PCN170
DIRECT COSTS OF HEAD AND NECK CANCER IN THE US: AN ANALYSIS USING
2008 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Rascati ME1, Park H2, Rascati KL2
1Texas Hospital Association, Austin, TX, USA, 2University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To estimate direct annual healthcare utilization and costs of for pa-
tients with head and neck cancer. METHODS: The 2008 Medical Expenditure Panel
Survey (MEPS) database, a nationally representative annual survey of the civilian
non-institutionalized population of the U.S was used. Patients’ data were extracted
if they had a Clinical Classification Code (CCC) for head and neck cancer (code 11)
and International Classification of Disease 9 (ICD-9) code of 140.xx-149.xx or
160.xx-161.xx. The SURVEYREG procedure in SAS for weighted populations was
used. RESULTS: Only 17 patients (representing 223,263 persons) met inclusion cri-
teria, therefore weighting may not be robust. Direct unweighted medical costs
attributable to cancer were estimated at $6,171  11,288 (mean  standard devia-
tion) per patient. Approximately half ($ 2860 6399) of this estimate was generated
by outpatient costs. Physician office visits ($1,609 4,291) and inpatient hospital
visits ($1225 5054) contributed to most of the remaining costs. If MEPS weightings
were used, the total costs were estimated at $ 8629 - again with about half gener-
ated by outpatient costs, and the majority of remaining costs split between office
visits and hospitalizations. Since MEPS only provides 3 digits of the 5-digit ICD-9,
some patients may have been missed as we did not include some ICD9s listed by
CCC 11; such as 195.xx “Malignant neoplasm of other and ill-defined sites” nor
230.xx “Carcinoma in situ of digestive organs” which included some cancers re-
lated to the head and neck (e.g. 230.0 - Carcinoma in situ of lip oral cavity and
pharynx) as well as others not related to these areas (e.g. 230.3 - Carcinoma in situ
of colon). CONCLUSIONS: The sample size was small in this database. Future stud-
ies should be conducted using databases with more patients and/or a more precise
level of diagnosis coding.
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OBJECTIVES: According to a report from the Rarer Cancers Foundation of England,
within the first six months of the launch of the Cancer Drugs Fund in England, only
£ 27,437,466 were used while the total amount allocated for the same period was
£50,000,000. This means that only a 56% of allocated funds for that period were
used. In a health system that restricts access to those oncological treatments that
have not shown to be cost-effective or have not been assessed by NICE a more
optimal use of the available funds would have been expected. In this study the
authors try to explore and determine the possible underlying reasons for the ob-
served underspent of allocated budget within the Cancer Drugs Fund in England
from October 2010 to March 2011. METHODS: Interviews were conducted across
different SHAs (Strategic Health Authorities) in England (n5) in 2011. A specific
questionnaire was designed to conduct this research RESULTS:Majority of respon-
dents mentioned delays in application for drug funding, miscalculation of expected
number of application by clinicians, among other reasons for underspent of Cancer
Drugs Fund CONCLUSIONS: SHAs should make sure that funds are properly allo-
cated and used in the benefit of patients and no application should be rejected in
the basis of an economic reason but just on pure clinical reasons
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OBJECTIVES: Analyzing the cancer incidence and TNM – classification is done by
national statistic in high spatial resolution, but no detailed data regarding pre-
existing illnesses and treatment pathways are gathered. That is why these prob-
lems are focused on using billing data from extramural and intramural anony-
mised patients datasets extended by drug prescription information. METHODS:
Starting with anonymized single person spatio-temporal hospital data including
diagnoses coded by ICD10, medical attendance data and patient identity key a
pre-selection is realized. In the next step the intramural patient history is focused
on, detecting the first indicated hospitalization. Afterwards criteria for the number
of reuptakes as well as for exclusion of cases (filtering not new diseases) are defined
based on the intramural patient history. Analyzing cancer indicated drug admin-
istration and drug prescription the year before the first hospitalization, knowledge
about risk groups is collected and evaluated. Additionally the probability of surviv-
ing regarding different treatment courses is measurable. These calculations are
done exemplary. RESULTS: Comparing the incidences calculated out of casemix
datasets for liver cancer, lung cancer and mamma carcinoma high accordance
comparing to cancer registry of Austria is observed. In case of liver cancer the
overall deviation is 14 cases per year; equal to a difference of 1.5 percent. In case of
mamma carcinoma 4882 detected new infections in control year 2007 are faced
with 4833 new cancer diseases registered by national statistics. CONCLUSIONS:
Using detailed single person spatio-longitudinal billing datasets in combination
with extended search strategies using exclusion criteria based on expert knowl-
edge as well as data structure information and modeling skills, highly reliable
datasets are edited. The analyzed background knowledge can be used in modern
dynamical simulation models producing reliable results.
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OBJECTIVES: European payer authorities reimburse the administration of antican-
cer agents for mNSCLC patients according to diverging tariffs and varying codes.
This poses the question of whether there is the need for a sensitivity analysis of
administration costs in health economic models when applied in France, Germany,
Italy, Spain, and the UK. METHODS: Two systematic literature reviews of the bib-
liographic database Medline were performed in order to identify relevant publica-
tions (of year 2000) on administration costs of chemotherapy for the treatment of
NSCLC. The review was supplemented by a search in the databases of the Cochrane
Library, EMA-EPAR, and ClinicalTrial.GOV. In addition, treatment guidelines, reim-
bursement databases, and national reimbursement tariffs were hand-searched.
Semi-structured interviews with expert oncologists were completed. Data extrac-
tion and evidence synthesis from these sources formed the basis of this evaluation.
RESULTS: Twenty-three manuscripts, 108 phase III study protocols, 6 EMA-labels,
and 12 European treatment guidelines were included in the analysis. The ten
NSCLC antineoplastic drugs mentioned in the ESMO and NCCN guidelines cover a
wide set of administration patterns with respect to 1st or 2nd line monotherapy,
combination therapy, and mono-or combination-maintenance therapy. The treat-
ment schedules vary in dose per application, composition per cycle, and number of
cycles. The main tariff for France is GHS 9606/GHM 28Z07Z (€386), for Germany
daycase DRG 71B (€720) and several separate agreements (“Onkologievereinba-
rung”) and for the UK daycase HRG SB97ZSB13Z (£399). For Italy and Spain the
actual DRG values vary tremendously, for instance in Italy for DRG410 (€310 for
Emilia Romagna vs. €40 for Basilicata), and in Spain C.6 for Galicia (€170) or 1.7.2.2
for Asturia (€149). CONCLUSIONS: The difference in treatment schedules in com-
bination with the variation in national administration tariffs shows the importance
of a sensitivity analysis when conducting a health economic analysis of NSCLC
administration costs in Europe.
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OBJECTIVES: In January 2009, the National Institute for Health and Clinical Excel-
lence (NICE) adopted an evaluation process for life-extending end-of-life treat-
ments. For eligible drugs, QALYs are weighted to favour the incremental cost-
utility ratios (ICUR). Also, patient access scheme (PAS, pricing agreements) are
sometimes established between the NHS and drug manufacturers to lower the
economic impact of costly drugs. The purpose of this study was to document the
effects of the end-of-life evaluation process (EOL) on anticancer drugs listing
recommendations. METHODS: NICE website was searched to identify published
technology appraisal guidances of anticancer drugs issued between January 2009
and May 2011. We documented EOL and PAS status, the listing recommendation
and the supporting ICURs. Positive and negative recommendations were stratified
by EOL and PAS status. RESULTS:We retrieved 32 recommendations among which
50% were approvals. The proportion of accepted drugs tends to be higher among
those evaluated with the EOL (9/16; 56%, p0,8). The ICURs of positive recommen-
dations associated with drugs not eligible or not considered for the EOL were
mostly comprised between 20,000£/QALY and 30,000£/QALY gained. On the other
hand, ratios of positive recommendations for drugs eligible to the EOL were higher
and varied from 30,350£/QALY to 54,366£/QALY gained. Among drugs evaluated
with the EOL, the proportion of accepted drugs analysed with PAS (6/9; 67%, p0,51)
tends to be higher than for drugs accepted without PAS. CONCLUSIONS: Despite
the small number of evaluations since its implementation, we observed with the
EOL a higher ICUR threshold that may have led NICE to recommend to list more
anticancer drugs that it would have been without the EOL. When the EOL was
considered, PAS also seems to have contributed to a higher rate of positive listing.
These findings have raised questions about the economic evaluation of anticancer
drugs in Canada.
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OBJECTIVES: To understand relative price differential for cancer drugs in the US
and the UK. Develop implications for pricing strategy and patient access for cancer
drugs. METHODS: Ten branded cancer drugs were selected and their prices for
similar dose and packaging were compared in the US and the UK. Prices were
analyzed for the end of 2010 and early 2011. Historical exchange rates were used to
convert British pounds to US dollars. Relative price discount was calculated for all
selected cancer drugs. KOLs and payers were interviewed to understand current
and future implications of this price differential. RESULTS: The median price dis-
count for selected ten branded cancer drugs in the UK versus the US was50%. The
range of discount for 10 branded cancer drugs was 27%-61%. The price discount for
oral small molecule drugs was higher than for biologics (55% versus 45%). Since UK
is one of the few remaining free pricing markets in Europe, other European markets
are likely to have even higher discounts relative to the prices in the United States.
Due to rising coinsurance of speciality products, US cancer patients bear signifi-
cantly higher cost than patients in the UK. KOL and payer interviews suggest US
pricing trends for cancer drugs are unlikely to be sustained at this level in the
future. CONCLUSIONS: US cancer drug prices are significantly higher than the
prices in the UK. This price differential is unlikely to be sustained in the future.
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OBJECTIVES: Objective of this study was to assess reimbursement outcomes and
patient access to oncology drugs in Croatia. National Institute of Clinical Excellence
(NICE) cancer guidelines and National Comprehensive Cancer Network (NCCN)
guidelines were used as benchmark. NICE is known for being committed to com-
plying with legal obligations on equity and human rights, conducting their work
based on identified cost effectiveness thresholds and known to be restrictive in
their recommendations. On the other hand, NCCN professional guidelines are key
international guidelines for oncology professionals which have been accepted and
followed worldwide. METHODS: Reimbursement processes, specific indications
and restrictions for 23 studied cancer drugs, ATC L01 class (antineoplastic agents)
have been analyzed and compared to UK NHS funding and reimbursement recom-
mendations given through NICE cancer guidelines as well as recommendations
given through NCCN guidelines. RESULTS: Studied cancer drugs were used for the
treatment of 14 different tumor locations: breast, colon, lung, leukemia, renal,
GIST, ovary, lymphoma, glioblastoma, prostate, liver, gastric, myeloma. Among 57
registered indications, Croatian Health Insurance Fund has in total reimbursed 43
(75%) while NICE has issued positive recommendations for only 35 (60%). On the
other hand, all investigated drugs and relevant indications except of one partially
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